Improving the Standard of Care for Solid Tumor Cancers

Improving Patient
Outcomes in
Solid Tumor
Cancer Treatment

BIO300
A New Class of Cancer Drug
Keeping America Safe

BIO300
Protecting Civilians, First Responders and Our Military
from Nuclear Accidents and Terrorism

BIO 300 improves outcomes for cancer patients receiving radiation treatments.

BIO 300 prevents and mitigates acute and delayed radiation injuries from nuclear accidents or acts of terrorism.

Humanetics News

Humanetics Corporation Invited to Present Data on BIO 300 at Government Conference
Read More

Humanetics Corporation Presents Data on BIO 300 at Radiation Research Society Annual Meeting
Read More

Humanetics Corporation Awarded Patent for Oral Drug to Protect Warfighters and First Responders from Radiation Injury
Read More

Humanetics Corporation Awarded Federal Contract to Develop New Radiation Countermeasure to Protect the Lungs
Read More

Humanetics Corporation Presents at 2018 BIO CEO and Investor Conference
Read More

Humanetics Corporation Presents Data on Drug to Protect Cardiac Cells Against Toxicity From Space-Like Radiation

Vice Admiral Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Humanetics' Medical Advisory Board

Humanetics Presents Data for Cancer Drug

Humanetics Receives New Grant from NASA

Humanetics Receives $3.8 Million Grant from Department of Defense

Humanetics Receives Patent for Cancer Drug

Humanetics to Present at Department of Defense Scientific Meeting